← Back to Screener
Valneva SE American Depositary Shares (VALN)
Price$5.95
Value ScoreC
Growth ScoreB
Momentum ScoreD
Favorite Metrics
Price vs S&P 500 (26W)-46.61%
Price vs S&P 500 (4W)10.86%
VGM Score51.43
Market Capitalization$577.23M
All Metrics
Book Value / Share (Quarterly)$0.71
P/TBV (Annual)7.66x
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)-21.52%
Cash Flow / Share (Quarterly)$-0.39
Price vs S&P 500 (YTD)-39.86%
Gross Margin (TTM)29.15%
Net Profit Margin (TTM)-38.70%
EPS (TTM)$-1.13
10-Day Avg Trading Volume0.69M
EPS Excl Extra (TTM)$-1.13
Revenue Growth (5Y)9.62%
EPS (Annual)$-0.80
ROI (Annual)-36.75%
Gross Margin (Annual)38.66%
Net Profit Margin (5Y Avg)-39.98%
Cash / Share (Quarterly)$0.74
Revenue Growth QoQ (YoY)76.88%
ROA (Last FY)-28.88%
Revenue Growth TTM (YoY)29.55%
EBITD / Share (TTM)$-0.64
ROE (5Y Avg)-60.52%
Operating Margin (TTM)-27.38%
Cash Flow / Share (Annual)$-0.39
P/B Ratio4.67x
P/B Ratio (Quarterly)6.05x
Net Income / Employee (Annual)$-193,444
EV / Revenue (TTM)1.84x
Net Interest Coverage (TTM)-2.56x
ROA (TTM)-37.47%
EV / EBITDA (TTM)23.53x
EPS Incl Extra (Annual)$-0.80
Current Ratio (Annual)2.38x
Quick Ratio (Quarterly)1.85x
3-Month Avg Trading Volume1.32M
52-Week Price Return-5.22%
Revenue / Employee (TTM)$539,778
Tangible BV / Share (Quarterly)$0.56
P/S Ratio (Annual)2.84x
Asset Turnover (Annual)0.44x
52-Week High$5.42
Operating Margin (5Y Avg)-28.31%
EPS Excl Extra (Annual)$-0.80
CapEx CAGR (5Y)-25.46%
Tangible BV CAGR (5Y)14.81%
26-Week Price Return-30.68%
Quick Ratio (Annual)1.85x
13-Week Price Return-46.30%
Total Debt / Equity (Annual)1.95x
Current Ratio (Quarterly)2.38x
Enterprise Value$690.97M
Revenue / Share Growth (5Y)-3.10%
Asset Turnover (TTM)0.71x
Book Value / Share Growth (5Y)-6.39%
Revenue / Employee (Annual)$293,312
Inventory Turnover (Annual)2.06x
Pretax Margin (Annual)-65.34%
Cash / Share (Annual)$0.74
3-Month Return Std Dev95.53%
Gross Margin (5Y Avg)34.55%
Net Income / Employee (TTM)$-283,407
EBITDA CAGR (5Y)41.51%
ROE (Last FY)-108.50%
Net Interest Coverage (Annual)-3.11x
EPS Basic Excl Extra (Annual)$-0.80
P/FCF (TTM)35.38x
Receivables Turnover (TTM)10.20x
Total Debt / Equity (Quarterly)1.95x
EPS Incl Extra (TTM)$-1.13
Receivables Turnover (Annual)5.54x
ROI (TTM)-47.24%
P/S Ratio (TTM)1.54x
Pretax Margin (5Y Avg)-39.29%
Revenue / Share (Annual)$1.21
Tangible BV / Share (Annual)$0.56
Price vs S&P 500 (52W)-33.43%
Year-to-Date Return-29.75%
5-Day Price Return0.12%
EPS Normalized (Annual)$-0.80
ROA (5Y Avg)-17.08%
Net Profit Margin (Annual)-65.95%
Month-to-Date Return12.98%
Cash Flow / Share (TTM)$-0.23
EBITD / Share (Annual)$-0.54
Operating Margin (Annual)-46.98%
LT Debt / Equity (Annual)1.52x
ROI (5Y Avg)-26.83%
LT Debt / Equity (Quarterly)1.52x
EPS Basic Excl Extra (TTM)$-1.13
P/TBV (Quarterly)7.66x
P/B Ratio (Annual)6.05x
Inventory Turnover (TTM)2.97x
Pretax Margin (TTM)-37.91%
Book Value / Share (Annual)$0.71
Price vs S&P 500 (13W)-56.05%
Beta2.01x
P/FCF (Annual)4.19x
Revenue / Share (TTM)$2.13
ROE (TTM)-109.23%
52-Week Low$2.13
vGradeC
gGradeB
mGradeD
vgmGradeC
Show chart for
Analyst Recommendations
Feb 2026
Mar 2026
Apr 2026
May 2026
4.09
4.09
4.08
4.08
Industry Peers — Biological Products(178)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
VALNValneva SE American Depositary Shares | C | B | D | $5.95 |
| AMGNAmgen Inc | C | C | C | $329.13 |
| GILDGilead Sciences Inc | C | B | C | $131.10 |
| ARGXargenx SE American Depositary Shares | D | A | C | $836.09 |
| RVMDRevolution Medicines, Inc. Common Stock | F | — | A | $163.68 |
| BIIBBiogen Inc. Common Stock | B | D | B | $192.23 |
| BNTXBioNTech SE American Depositary Share | C | C | C | $91.70 |
| MRNAModerna, Inc. Common Stock | C | B | B | $46.06 |
| NBIXNeurocrine Biosciences Inc | C | B | B | $161.00 |
| EXELExelixis Inc | C | B | B | $50.28 |
| KRYSKrystal Biotech, Inc. Common Stock | D | B | B | $298.10 |
About
Valneva SE is a vaccine company with marketed products for travelers, including IXIARO, DUKORAL, and IXCHIQ. The company generates revenue primarily from vaccine sales while maintaining development programs for new vaccine candidates and COVID-19 vaccine initiatives. Additional revenue streams include technology licensing and manufacturing services.